METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo for tough prostate cancer hits roadblock
Disease control TerminatedThis study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with a hard-to-treat type of advanced prostate cancer that had stopped responding to hormone therapy. The goal was to find the best dose and see if…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
Experimental drug acapatamab targets Hard-to-Treat prostate cancer
Disease control TerminatedThis early-stage study tested a new drug called acapatamab in 212 men with metastatic castration-resistant prostate cancer that had stopped responding to standard therapies. The drug works by helping the body's immune cells attack cancer cells that have a specific marker (PSMA) o…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
Engineered t cells take aim at hard-to-treat prostate cancer
Disease control TerminatedThis early-stage study tested a new treatment called BPX-601 for people with advanced prostate cancer that had stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells carrying a specific marker (PSCA). …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
Experimental prostate cancer pill trial halted early
Disease control TerminatedThis early-stage trial tested a new drug called TQB3720 in men with advanced prostate cancer that had stopped responding to hormone therapy. The goal was to find a safe dose and see how the drug moves through the body. The study was stopped early, so results are limited.
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:06 UTC
-
New combo for tough prostate cancer shows promise, but trial halted
Disease control TerminatedThis study tested a new drug called exicorilant (CORT125281) combined with enzalutamide in men with metastatic castration-resistant prostate cancer (a type that has spread and stopped responding to hormone therapy). The goal was to find a safe dose and see if the combo could help…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 26, 2026 03:05 UTC
-
Cancer drug combo trial halted early after enrolling only 13 patients
Disease control TerminatedThis study tested a drug called zenocutuzumab combined with other medicines in people with two types of cancer: non-small cell lung cancer with an NRG1 gene fusion, and metastatic prostate cancer that no longer responds to hormone therapy. The trial was stopped early after enroll…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Partner Therapeutics, Inc. • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
New prostate cancer drug study halted early
Disease control TerminatedThis study aimed to test the safety and effectiveness of new drugs for men with a type of advanced prostate cancer that no longer responds to hormone therapy. It enrolled 65 adults with confirmed cancer. The study was terminated early, so results are limited.
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 15, 2026 11:56 UTC